Overview

A Clinical Trial With KJ103 in Anti-GBM Disease

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

An open-label, single-arm Phase II study to evaluate the preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of KJ103 in patients with anti-GBM disease.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Bao Pharmaceuticals Co., Ltd.

Treatments:

Cyclophosphamide
Glucocorticoids
Injections
Plasma Exchange